Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations were $5.04. Operator: My name is Julienne, and I will be your conference ...

Q4 2024 . Management View. Amgen highlighted its robust performance in 2024, achieving 14 products annualizing over $1 billion in ...

Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

The successful integration of the Horizon franchise, bolstered by Tepezza's approval in Japan and Uplizna's positive clinical results, adds to Amgen's growth potential. Amgen is also investing in ...

As for biosimilars, CHMP regulators signed off on Dyrupeg, a copycat of Amgen’s post-chemo infection prevention Neulasta by Aurobindo Pharma’s CuraTeQ Biologics, plus Amgen’s Pavblu and Skojoy.

Asian shares are trading mostly higher after a Wall Street rally that followed profit reports from major companies.

The National University of Singapore is offering its Amgen Scholars Asia Program for another year ... The application deadline is on March 31, 2025. 5. ADB-Japan Scholarship Program The Philippines is ...

Amgen’s osteoporosis bone-forming drug Evenity (romosozumab) has been approved in Japan, ahead of a crunch review by advisers to the US regulator later this month. Evenity could have been on the ...

Separately, Synaffix on Thursday also unveiled an ADC technology licensing deal with Japan's Mitsubishi Tanabe ... having penned deals with the likes of Amgen, ADC Therapeutics, Genmab, Innovent ...

Amgen and UCB finally have FDA approval for osteoporosis ... and also after the drug was given the go-ahead in Japan. Romosozumab is also under regulatory review by the EMA. Nevertheless, Evenity ...